Travere Therapeutics officer proposes $303K share sale
The notice separately lists 92,241,550 common shares outstanding.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Travere Therapeutics, Inc. officer Jula Inrig gave notice of a proposed sale of 7,215 common shares, with an approximate sale date of April 14, 2026 and an aggregate market value of $302,515.98. Morgan Stanley Smith Barney is named as the broker.
The shares were acquired through performance restricted stock unit vesting on April 13, 2026. The remarks say the sale is required under the issuer’s equity incentive plans to fund tax withholding through a brokerage firm designated by the issuer, and is not discretionary. Elizabeth E. Reed signed as attorney-in-fact for Inrig.
Key Figures
Key Terms
Performance Restricted Stock Unit Vesting technical
sell to cover financial
tax withholding obligation financial
equity incentive plans financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.